The importance of transforming growth factor beta (TGFb) as an immune regulatory cytokine in atherosclerosis has been established. However, the role of TGFb signalling in dendritic cells (DCs) and in DC-mediated T cell proliferation and differentiation in atherosclerosis is unknown.
Aims
The importance of transforming growth factor beta (TGFb) as an immune regulatory cytokine in atherosclerosis has been established. However, the role of TGFb signalling in dendritic cells (DCs) and in DC-mediated T cell proliferation and differentiation in atherosclerosis is unknown.
Methods and results
Here, we investigated the effect of disrupted TGFb signalling in DCs on atherosclerosis by using mice carrying a transgene resulting in functional inactivation of TGFb receptor II (TGFbRII) signalling in CD11c + cells (Apoe CD11cDNR mice strongly induced T-cell proliferation and activation, resulting in increased amounts of effector T cells producing high amounts of Th1 (IFN-g), Th2 (IL-4, IL-10), Th17 (IL-17), and Treg (IL-10) cytokines.
Conclusion
Here, we show that loss of TGFbRII signalling in CD11c + cells induces subtle changes in DC subsets, which provoke uncontrolled T cell activation and maturation. This results in increased atherosclerosis and an inflammatory plaque phenotype during hypercholesterolaemia.
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Introduction
The adaptive immune system plays a crucial role in atherosclerosis. Different T cell subsets, B cells, and natural killer (NK) T cells modulate atherosclerotic plaque progression, plaque inflammation, and athero-thrombosis. 1 The polarization of the immune response determines whether a response is pro-atherogenic or antiatherogenic: differentiation of T cells along the Th1-pathway are pro-atherogenic, along the Treg pathway are anti-atherogenic, and along the Th2 and Th17 pathway either pro-or anti-atherogenic. 1 Dendritic cells (DCs) have a central role in initiating and regulating immune responses and especially T cell responses, 2 both in lymphoid and peripheral tissue. It has become evident that many distinctive DC subtypes exist, each with a particular location, a specialized function in the immune system and expressing a unique set of cell surface markers. 3, 4 Commonly, DCs are classified in the CD11c hi MHCII + conventional DCs (cDCs) and the non-conventional DCs. cDCs are subdivided into migratory and lymphoid-tissue-resident DCs (which can be further divided into two subsets; the CD8 + cDC and the CD8 2 cDC). 5 The non-conventional DCs consist of the plasmacytoid (p)DCs and monocyte-derived DCs. Plasmacytoid DCs are found in many tissues including blood, thymus, bone marrow, liver, and lymphoid organs. Plasmacytoid DCs are known to secrete large amounts of type I interferons (IFNs) and have been associated with the preservation of peripheral tolerance and with the initiation of autoimmune responses. 3 However, the specific role of these distinct DC subsets in atherosclerosis remains to be elucidated. 6 In the vasculature, DCs are present in the arterial intima 7 and were recently ascribed an immune-modulatory role in atherosclerosis. 8 Intimal DCs are able to accumulate lipid. 9 In more advanced stages of atherosclerosis, DCs were found to affect plaque growth as well as cholesterol homeostasis. Hypercholesterolaemic mice containing DCs with an enhanced lifespan and immunogenicity (DC-hBcl2Apoe 2/2 DC-hBcl2Ldlr 2/2 mice) had increased Th1 and Th17 cytokine expression levels, but decreased plasma cholesterol levels, and no change in the atherosclerotic plaque area. 6 In contrast, Apoe 2/2 mice in which DCs were depleted (CD11c-DTRApoe 2/2 ) mice had increased cholesterol levels. 10 Vaccination using mature DCs pulsed with oxidized low-density lipoprotein (oxLDL) reduced lesion size, 11 whereas vaccination with malondialdehyde (MDA)-LDL pulsed DCs aggravated atherosclerosis, 12 illustrating the tight and complex modulation of atherosclerosis by DCs in different conditions. Other studies stressing the importance of DC-T cell interactions in atherosclerosis are interventions in co-stimulatory molecules such as CD80/86, CD40/CD40L, OX40L/OX40, CD137 and ICOS, which are all pivotal for DC-mediated T cell proliferation and polarization. 13 -18 For example, we have shown that inhibition of CD40L, CD40, or CD40-TNF-Receptor Associated Factor (TRAF) 6 interactions reduces atherosclerosis by affecting T cell activation, polarization, and monocyte activation, and by upregulating the anti-inflammatory cytokine transforming growth factor beta (TGFb). 19 -21 Transforming growth factor beta is a powerful modulator of immune responses. It not only regulates immune responses by inhibiting the proliferation of naïve and activated T cells, and by mediating T cell polarization, but also has a crucial role in mediating DC functions. 22, 23 
Methods
Apoe 2/2 CD11c-dnTGFbRII transgenic mice
CD11c-dnTGFbRII (CD11cDNR) mice were generated as described previously and were backcrossed to Apoe 2/2 mice. 25 The transgene was composed of the human TGFb type II receptor sequence ( -7 and +573) that encodes for the extracellular and transmembrane regions, but not the intracellular region of the TGFb type II receptor, thereby preventing TGFb signalling. 25 Genotypes were verified by polymerase chain reaction (PCR) as described before and hemizygous transgenes and their littermate wild types (both Apoe 2/2 ) were used.
The animals were fed a normal chow diet and at the age of 20 weeks, mice (n ¼ 34) were euthanized. Blood was obtained from the retro-orbital plexus and spleen, liver and lymph nodes were harvested after in situ perfusion using PBS followed by 1% paraformaldehyde. Hearts were isolated and frozen in Tissue-Tek (Shandon, Veldhoven, The Netherlands). Other organs collected during autopsy were fixed in 4% paraformaldehyde. All animal experiments were performed under approved Institutional Animal Care and Use Committee protocols of the respective universities.
Histology and morphometry
The plaque area was analysed in the aortic root using serial 6 mm sections with 42 mm intervals, beginning from the onset of the aortic valves until the valves had disappeared. For histological analysis of atherosclerosis, sections were stained with haematoxylin and eosin (HE). The plaque area was measured on a Leica DM3000 Light microscope (Leica Microsystems) coupled to a computerized morphometry system (Leica Qwin 3.5.1).
Immunohistochemistry
Consecutive sections were immunolabelled with anti-CD45 rat monoclonal antibody (1:5000; BD Biosciences) to detect all inflammatory cells, anti-Moma-2 rat monoclonal antibody (1:50; Serotec) to detect macrophages, anti-aSMA monoclonal mouse antibody (1:500; DAKO) as a marker of vascular smooth muscle cells and myofibroblasts and anti-MMP9 goat polyclonal antibody (1:200; Santa Cruz) to detect matrix metalloproteinase 9. Anti-CD3 rabbit monoclonal antibody (1:200; DAKO) was used to detect T lymphocytes, and anti-CD4 and anti-CD8 rat monoclonal antibodies (undiluted, gift from W. Buurman, Department of General Surgery, Academic Hospital Maastricht) to distinguish between T-helper cells and cytotoxic T-cells, respectively. Sirius red staining was used to detect collagen content, both by brightfield-and polarization light microscopy. Morphometric analyses were performed using a Leica Quantimet with Qwin3.5.1 software (Leica Microsystems).
Fluorescent immunohistochemistry was used to determine the presence of CD11c + cells in the aortic lesions. CD11c, CD11b, DX5, CD4, and CD8 antibodies (all BD Biosciences) were conjugated to fluorescein isothiocyanate (FITC), phycoerythrin (PE), or peridinin chlorophyll protein (PerCP). Sections were analysed with a Leica TCS SP5 multi-photon microscope (Leica).
Lipids and lipoproteins
Plasma cholesterol and triglyceride levels were measured using colorimetric assays (Roche). Size fractionation of lipoproteins was performed by fast-performance liquid chromatography (FPLC) using a 30 × 0.32 cm Superose 6B micro-FPLC column (GE Healthcare) followed by in-line cholesterol detection, as described previously. 26 
Antibody measurements
Antibody (Ab) titres to Cu 2+ -LDL and MDA-LDL were measured in the plasma as previously described. 27 In brief, copper-oxidized LDL (CuOx-LDL) and malondialdehyde-modified LDL (MDA-LDL) were generated from freshly isolated human LDL. Binding of specific IgM, IgG1, and IgG2c antibodies in individual plasma samples to coated antigens were measured by chemilluminescent enzyme-linked immunosorbent assay (ELISA) at indicated dilutions. Bound antibodies were detected using alkaline phosphatase (AP)-conjugated goat-anti-mouse IgM or biotinylated goat-anti-mouse IgG1 and goat-anti-mouse IgG2c (Jackson Immuno Research) followed by AP-conjugated Neutravidin (Thermo Scientific).
Real-time polymerase chain reaction
RNA was isolated from cultured bone marrow-derived macrophages using the RNeasy Mini kit II (Qiagen). One microgram of total RNA was reverse transcribed into cDNA using the SuperScript w VILO TM cDNA Synthesis Kit (Invitrogen). Real-time PCR reactions (7900HT Fast Real Time PCR system, Applied Biosystems) were carried out with cDNA (equivalent to 10 ng total RNA), TaqMan w Fast Advanced Master Mix, and TaqMan w Gene Expression assays (all Applied Biosystems) for CD40, CD86, TNFa, MHCII, iNOS, Mannose receptor, Arginase 1, RELMa, and, Ym-1 according to the instructions of the manufacturer. Samples were assayed in quadruplicates. The mRNA expression was normalized to that of the housekeeping gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression.
Flow cytometry
Spleen and lymph nodes were harvested from the mice and single cell suspensions were prepared and stained with anti-TCR, -CD3, -CD4, -CD8, -CD25, -Foxp3, -CD44, -CD62L, -CD11c, -CD40, -MHCII, -CD86, -Ly6C, -CD19 (BD Biosciences), or isotype control IgG (all BD Biosciences). Antibodies conjugated to FITC, PE, allophycocyanin (APC), or PerCP were used and cells were analysed using a FACSCanto II (BD Biosciences). 
Cell culture
Bone marrow-derived dendritic cells/ macrophages
Femurs and tibiae were removed and the ends of the bones were carefully cut off. The bone marrow was flushed out and filtered. Red blood cells were lysed and the cells were counted and adjusted to 0.5 × 10 6 cells/mL by adding RPMI 1640 containing 10% heat-inactivated FCS, glutamine, 100 U/mL penicillin/streptomycin, and 50 mM b-Mercaptoethanol. Granulocyte-macrophage colony-stimulating factor (20 ng/mL) was added to generate DCs. At day 10, 99% of the cells were CD11c + . A similar protocol was used to obtain macrophages where L929-conditioned medium (M-CSF) was added.
Cell culture, proliferation, and cytokine assays Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% FCS, 0.02 mM 2b-mercaptoethanol, and antibiotics. For cytokine measurements, bone marrow-derived CD11c + cells (2 × 10 6 cells/well)
were stimulated with LPS (10 mg/mL) and IFNg (100 U/mL) for 48 h. TNFa and IL-12 production in the supernatants were measured using specific ELISAs (R&D Systems). CD4 + T cells were cultured at 1 × 10 5 cells/well for 48 h in anti-CD3-coated microplates (10 mg/mL) either alone or with CD11c + cells (2 × 10 4 cells/well). Cytokine production in the supernatants was measured using specific ELISAs (R&D Systems). For proliferation, cells were cultured at 378C for 72 h and pulsed with 1 mCi of [ 
Statistical analysis
Values are expressed as mean + SEM. A non-parametric MannWhitney U test (two-tailed), or, when appropriate, a student's t-test was performed (two-tailed). Statistical analysis was performed using Prism (GraphPad). Probability values of P , 0.05 were considered significant.
Results
Localization and subtype of CD11c CD11cDNR mice ( Figure 2D ). 30 Indeed, TNFa and IL12 production were increased in in vitro matured and stimulated CD11cDNR DCs ( Figure 2E 
Anti-malondialdehyde-LDL or oxLDL antibodies
We next tested whether deficiency of TGFbRII signalling in DCs would change antibody titres or subtypes of IgG antibodies directed against modified LDL in the plasma of Apoe 2/2 Cd11cDNR mice. However, no significant differences in plasma titres of IgG1, IgG2b, IgG2c, or IgM antibodies against Cu 2+ -oxLDL and MDA-LDL could be detected between the two groups of mice ( Figure 4G ).
Deficient transforming growth factor beta receptor II signalling in dendritic cells accelerates atherosclerosis and promotes T cell influx in atherosclerotic plaques
At sacrifice, body weight of Apoe 2/2 and Apoe 2/2 CD11cDNR mice was similar. Surprisingly, Apoe 2/2 CD11cDNR mice had decreased total plasma cholesterol levels, particularly in the chylomicron remnant/VLDL fraction, while plasma triglycerides did not differ (see Supplementary material online, Figure S4 ). Despite the decrease in total cholesterol levels, Apoe
2/2
CD11cDNR mice exhibited a two-fold increase in atherosclerotic plaque area in the aortic root ( Figure 5A , C, D) and a two-fold increase in the percentage of stenosis ( Figure 5B ) compared with the Apoe 2/2 littermates. Plaque CD45 + leucocyte content was strongly increased in Apoe 2/2 CD11cDNR animals compared with controls ( Figure 6A-D) , consistent with the increase in effector memory T cells (Figure 4) . To more precisely define the actual leucocyte subsets that were increased in Apoe 2/2 CD11cDNR mice, we analysed the lesions for the presence of different T cell (CD3, CD4, CD8, Foxp3), and macrophage markers (Moma-2). Plaques of Apoe 2/2 CD11cDNR mice contained significantly more CD3 + T cells then the controls (Figure 6E -H Figure S3D -G). Using real-time PCR, we could not detect any significant changes in expression of TNFa, CD206, Arginase-1, or YM1 (see Supplementary material online, Figure S3H ). These data suggest that the absence of TGFb signalling in CD11c + cells does not affect macrophage phenotype or alters the M1/M2 balance, but rather affects DC and T cell populations.
Atherosclerotic lesions of Apoe 2/2 CD11cDNR mice exhibit increased matrix turnover
In atherosclerotic lesions of Apoe 2/2 CD11cDNR mice, the sirius red positive area had significantly decreased compared with controls ( Figure 7A-C) . Polarization microscopy confirmed this decrease in collagen content, and revealed a shift towards the red spectrum, specifying thicker and more mature collagen fibres ( Figure 7A , D, E), probably reflecting the more advanced stage of the plaques in Apoe 2/2 CD11cDNR mice. This was accompanied by a decrease in a-smooth muscle cell actin + (ASMA) cell 
Discussion
The present study highlights the importance of TGFbRII signalling in DCs for the progression of atherosclerosis. The current experiments clearly show that the absence of TGFbRII signalling in DCs caused an increase in atherosclerotic plaque size, despite a 50% reduction in plasma cholesterol levels. Moreover, plaques contained more CD4 + and CD8 + T cells and less collagen and an increased matrix turnover, and generally were reminiscent of a vulnerable, rupture -prone plaque phenotype in humans. Several studies have provided evidence for an important role of TGFb as an immune modulating cytokine in atherosclerosis. Systemic inhibition of TGFb signalling in Apoe 2/2 mice by using a recombinant soluble TGFb type II receptor 31 or a blocking TGFb1 antibody 32 resulted in accelerated atherosclerosis. Lesions exhibited an unstable phenotype that contained low amounts of fibrosis, an increased amount of inflammatory cells, and even intraplaque hemorrhages. 31, 32 Cardiac overexpression of TGFb1, resulting in increased plasma levels of TGFb, limited plaque growth and induced plaque stabilization. 33 These effects have predominantly been attributed to TGFb signalling in T cells. Indeed, mice with abrogated TGFb signalling in T cells (Apoe 2/2 CD4-dnTGFbRII) also showed accelerated lesion progression, with plaques containing abundant inflammatory cells paralleled by a decrease in plaque fibrosis. 34, 35 The defect in TGFbRII signalling in T cells increased systemically the amount of Th1 and Th2 cytokines, with profound increases in plasma levels of IFNg, but also of IL-10 and IL-4. Gojova et al. 36 who transplanted bone marrow from CD2-dnTGFbRII mice into Ldlr 2/2 recipients obtained similar results in plaque phenotype, although plaque area decreased. The immune modulatory effects of TGFb are not restricted to T cells. Although TGFb producing Tregs are well known to control T cell activation and differentiation and play a crucial role in atherosclerosis, 22 the immune-regulatory capacity of other cell types is also controlled via TGFb. 24 Phagocytosis of apoptotic cells leads to TGFb secretion, which inhibits the production of inflammatory cytokines and chemokines (including IL-1b and TNFa) in macrophages. 37 Moreover, TGFb also inhibits macrophage activation and may be involved in polarization towards the M2 phenotype. 24 However, in our hands, disruption of the TGFb signalling in CD11c + cell did not affect macrophage polarization significantly, although M1 markers like CD40 showed a slight decrease, and expression of M2 markers such as Arginase-1 and the mannose receptor a slight increase. The exact role of TGFb in DC biology remains to be elucidated. What is known is that TGFb can immobilize tumour Langerhans cells, 38 and reduces their expression of MHCII, CD86, and CD40
as well as the production of IL-12, TNFa, and CCL5, thereby reducing its antigen-presenting capacity and DC-mediated T cell responses. 39 -41 In DC development, TGFb accelerates the differentiation of common DC progenitors (CDP) towards conventional CD8 + and CD8 2 DCs (cDC) and blocks the differentiation into pDCs. 42 Although the majority of these studies focused on Langerhans cells and tumour-associated DCs, these data corroborate our findings. We also observed increased DC cytokine production, which had massive effects on T cell activation and augmented T cell proliferation when TGFb signalling was abrogated in DCs in an atherosclerosis setting. However, in contrast to earlier findings, 42 inhibition of TGFb-signalling decreased the number of pDCs significantly. A recent report by Daissormont et al. 43 showed that inhibition of pDCs is associated with plaque progression and inflammation. Therefore, the observed decrease in pDCs in our mouse model is likely secondary to the increase in plaque area and plaque inflammation. TGFb signalling in CD11c , and Th17 T cell subsets. Especially, the Th1 subset is crucial for atherosclerosis, while the Th2 subset can be either pro-or anti-atherogenic. 1 The increase in Th17 cells is rather surprising, since TGFb was considered to be crucial for a Th17 response. However, Th17 cells can develop independently of TGFb 44 and the role of Th17 cells in atherosclerosis is still controversially discussed with some groups reporting a pro-atherogenic, 45 -47 and others an anti-atherogenic role for Th17 cytokines. 48 Interestingly, Apoe 2/2 CD11cDNR mice develop a compensatory Treg response, which was insufficient to prevent the increase in atherosclerosis. an interaction between TGFb, DCs, and cholesterol metabolism, which requires further investigation.
In conclusion, we observed that TGFbRII signalling in CD11c expressing cells plays a key role in the regulation of the activation of T cells during atherogenesis. More specifically, our data show that TGFb signalling in DCs modulates the interaction between the innate and adaptive immune response by affecting DC and T cell activation, thus dampening inflammation in atherosclerosis. Our data substantially contribute to the understanding of TGFb signalling in atherosclerosis and underline the important role of TGF-b in regulating immune responses in atherogenesis. Many TGFb agonists have been developed and their efficacy was tested in numerous animal models. 49 However, to apply activation of TGFb as a therapy for atherosclerosis, a number of obstacles need to be overcome. TGFb signalling is highly dependent on the environmental milieu and can be either beneficial or detrimental. In neoplastic disease for example, TGFb suppresses the progression of early tumours, but at more advanced stages of the disease cancer cells start producing TGFb, which then promotes metastasis. 37, 50 In addition, chronic administration of TGFb has been reported to induce interstitial fibrosis and hepatic fibrosis. 51 Targeted induction of TGF-b signalling in specific cells such as DCs and T cells might circumvent these adverse side effects. The results of this study will aid the development of immunotherapies to combat a broad range of inflammatory diseases.
Translational aspects/clinical perspectives
In the present paper, we discovered that TGFb expressed by DCs plays an important role in the modulation of the immune system during atherosclerosis, and consequently in mediating the progression of atherosclerosis. Dendritic cell-specific TGFb not only mediates DC polarization, but is even more important in keeping the different T-lymphocytes in control, both within the plaque and in blood and lymphoid organs. This renders TGFb as one of the most powerful regulators of the immune system in atherosclerosis.
Dampening of the immune responses by stimulation of TGFb would therefore slow down the progression of atherosclerosis and induce atherosclerotic plaques with a low inflammatory burden, thereby reducing the incidence of atherosclerotic plaque rupture and subsequent clinical symptoms such as myocardial infarction or stroke. Until now, different TGFb agonists have been developed and their efficacy was tested in numerous animal models. 49 However, besides an immune-modulatory cytokine, TGFb is also a profibrotic factor, and systemic therapy consequently induces interstitial and liver fibrosis. 51 Based on our present data, stimulation of TGFb in DCs only would still be beneficial for atherosclerosis by dampening immune responses, but may prevent the adverse effects of global TGFb stimulation.
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